tru Independence’s Immunogen Inc IMGN Stock Holding History

tru Independence’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	-$6	–	746
2020 Q4	$6	Buy	+1	New	+$6	﹤0.01%	604

Other funds holding IMGN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

tru Independence's IMGN Position: Q1 2021 in Review

tru Independence sold out of Immunogen Inc (IMGN) in Q1 2021, closing a stake of 1 share — an estimated $6 sold.

tru Independence first reported a position in IMGN in Q4 2020 and held it in 1 quarter. The position peaked at $6 in Q4 2020. 217 funds tracked by Wall St. Rank hold IMGN as of Q1 2021.

tru Independence reported no remaining Immunogen Inc position as of Q1 2021 after selling out during the quarter.
tru Independence sold 1 Immunogen Inc share in Q1 2021, an estimated $6.
tru Independence first reported a position in Immunogen Inc in Q4 2020 and held it in 1 quarter.
tru Independence's Immunogen Inc position peaked at $6 in Q4 2020.
217 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.